European journal of medicinal chemistry
Indexed In
ulakbim MEP: 745 Ödeme: 3725 Yılı: 2019
Short Name Eur J Med Chem
Abbreviated Name Eur J Med Chem
ISSN 1768-3254
Aim and Scope The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
Author Instructions
Keywords synthesis; Antimicrobial activity; Antifungal Activity; Medicinal Chemistry; Antimicrobial; antibacterial; resistance; Antifungal agents; Docking; Metronidazole; 1,2,3-Triazole; Anti-cancer activity; Hybrid; Invasion; Migration; Nucleobase; Cancer; Click chemistry; Inhibitors; NAD; Nicotinamide phosphoribosyltransferase; Cytotoxicity; 1,2,4-triazole; 3-Nitro-1,2,4-triazole; EGFR; Hypoxia; Tyrosine kinase inhibitor; VEGFR-2; Vandetanib; molecular docking; Breast cancer; biopolymers; biomass; Chemotherapy; Diabetes; green chemistry; phthalocyanine; anticancer; nanomaterials; cancer therapy; drug delivery; adjuvant; antiviral; apoptosis; estrogen receptor; long alkyl chains; selective estrogen receptor downregulators; structure-activity relationships; hiv-1; autophagy; malaria; molecular dynamics; antimicrobial peptides; selectivity; mitosis; allosteric modulation; secondary metabolites; zebrafish; epigenetics; anticonvulsant; tubulin polymerization; p53; anti-cancer; chalcone; docking study; alkylsulfanyl-triazoles; aryl-triazolethiones; drug design; parp-1; antitubercular; isatin; 1,2,3-triazoles; antibacterial activity; antiproliferative activity; plasmodium; glutathione; isoniazid; sulfonamides; antiviral activity; alzheimer's disease; antitumor; cyclooxygenase-2; drug combination; multidrug resistance; anti-metastatic activity; anticancer activity; bi(iii) complex; multi-targeting mechanism; gst; photodynamic therapy; gastric cancer; anti-inflammatory activity; de novo design; microarray; abstract; tumor; angiogenesis; benzothiazole; pyrazole; microtubule; anti-diabetic; anti-inflammatory; coumarin derivatives; bacterial resistance; amphiphilic aminoglycoside; antipseudomonal; galleria mellonella; rifampicin; synergy; p-glycoprotein; structure-activity relationship; heterocycles; qsar; graphene quantum dots; anti-dengue virus compounds; pharmacokinetics in vitro properties; c646; benzimidazole; chalcones; thiazole; hiv integrase; mt-4 cells; sulphadimidine; multicomponent reaction; telomerase; 5-fluorouracil; acetylcholinesterase; vitamin c; nos2; proteomic analysis; kinetic studies; intrinsic apoptosis; impact factor; her2; thiazolyl-pyrazoline; antidepressant; antibacterial agents; esbl; cytoskeleton; carbonic anhydrase; fusidic acid; tumor resistance reversal activity; 2, 8- diazaspiro[4.5] decan- 1- one; chitin synthase inhibitor; integrin; photosensitizer; antitumor activity; publication rate; kinase; peptidomimetics; hypoxia-inducible factor-1; beta-amino acids; carba; multi-resistant bacteria; smamps; synthetic mimics of antimicrobial peptides; organocatalysis; cinnamic acid derivatives; isobenzofuranone; leishmania braziliensis; leishmanicidal activity; benzenesulfonamide; ca isoforms; carbonic anhydrase inhibitors; tail approach synthesis; antiproliferation; combretastatin a-4; tubulin; antimycobacterial activity; action mechanism; hybrid molecules; chronic myeloid leukemia; ferrocene; anti-gastric cancer activity; tertiary sulfonamide; anti-fungal activity; anti-trypanosomal activity; antimalarial activity; cinnamamide; tyrosinase inhibitor; cox-2; renewable resources; macrolide antibiotics; resistant bacterial strains; ohira-bestmann reagent; heterocyclic; antitumoral; butenolide; hif-1; benzisothiazol; celecoxib; saccharin; 15-lipoxygenase; butyrylcholinesterase; cox-1/cox-2 inhibition assay; naproxen scaffold; 1, 2, 3-triazole; thymidylate synthase; uracil derivatives; plk1; covalent inhibitors; fragment-based drug design; fructose-1,6-bisphosphatase (fbpase); novel allosteric site; fungal infections; trimethoprim; lipophilicity; bivalent; p-gp; securinine; virosecurinine; hybrid compounds; tetrazole; cationic amphiphilic compounds; membrane-active molecules; paclitaxel chemosensitivity; benzotriazoles; sensitive tumor cell proliferation; p300 inhibitors; marine invertebrates; antipyrine; pyrazolone; schiffbase; cns agents; derivatives; 5-imidazopyrazole incorporated polyhydroquinolines; antituberculosis activity; acrylonitrile; nutrient starvation test; propanenitrile; pyrazolopyrimidines; chloroquine; covalent inhibitor; cyclin-dependent kinase 7; cdk2 inhibitor; ikk-β modulators; nf-κb signaling pathway; thiazolidine-2,4-diones; dpp-iv; druggability; gpr119; hbk001; xanthine compounds; 1,3-thiazoles; biological targets; cyclic peptides; sphingoid; myrrhanones b; isosteviol; structural modification; stevioside; lead exploration; steviol; in silico studies; α-amylase inhibition; α-glucosidase inhibition; amino acid conjugates; lipophilicity-activity relationship; antitcancer activity; jatrorrhizine derivatives; platinum(ii) complex; egfr tyrosine kinase; imidazo[4,5-c]pyridin-2-one; katanin; polymer-metal conjugates; ruthenium organometallic compounds; schiff's bases; marine microorganisms; marine natural products; rnase h; dual inhibitors; integrase; ledgf/p75 cellular cofactor; drug-resistant; colchicine binding site; shikonin-benzo[b]furan derivatives; tubulin polymerization inhibitors; annexin; quadrennial meeting; world society for stereotactic and functional neurosurgery; 3c protease; 3d pharmacophore; 4-phenylcoumarins; anti-hav; hydrazones; morpholin; cell death modulators; imatinib resistance; peroxisome proliferator-activated receptor γ activity; sartans; cyp3a4; caspases 3/7; coumarin hydrazide-hydrazone; radiolabeling; anti-mycobacterial activity; anti-tubercular activity; hydrazide-hydrazone derivatives; isoniazid derivatives; structure-active relationship; piperidines; quinolines; atx inhibitors; binding mode analysis; structure-based optimization; trifluoroacetyl hydrazone;